Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer

• Published in: International journal of cancer Vol. 131; no. 6; pp. E938 - E945
• Main Authors: Shen, Jie, Wang, Hao, Wei, Jia, Yu, Lixia, Xie, Li, Qian, Xiaoping, Zou, Zhengyun, Liu, Baorui, Guan, Wenxian
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.09.2012; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic - therapeutic use; Biomarkers; Biomarkers, Tumor - analysis; Cancer; cell-free mRNA; chemosensitivity; Chemotherapy; Female; Gastric cancer; Humans; Male; Medical research; Middle Aged; Plasma; Quinazolines - therapeutic use; raltitrexed; Ribonucleic acid; RNA; RNA, Messenger - analysis; RNA, Messenger - blood; Stomach Neoplasms - drug therapy; Stomach Neoplasms - enzymology; Thiophenes - therapeutic use; Thymidylate Synthase - antagonists & inhibitors; Thymidylate Synthase - genetics

Different chemotherapeutic agents currently available are effective only in certain subsets of patients. Predictive biomarkers will be helpful in choosing those agents and can improve the clinical efficiency by a more personalized chemotherapeutic approach. Raltitrexed is a novel water‐soluble quina...